Skip to Content
Suyu Liu

Suyu Liu

Regular Member

Assistant Professor

MDA FCT4.6032 (Unit 1409)

The University of Texas MD Anderson Cancer Center
Department of Biostatistics 

My research focuses on the development of novel adaptive designs for clinical trials, including phase I and phase I/II trial designs to find the maximum tolerated dose (MTD), dose-finding designs that accommodate late-onset toxicities, biomarker-based adaptive designs for targeted therapy development, and adaptive randomization that simultaneously balances covariates across treatment arms. I have proposed algorithm-based dose-finding designs that make optimal dose assignment to minimize the probability of inappropriate dose assignment for each patient. I have proposed a Bayesian phase I/II dose-finding trial design that simultaneously accounts for toxicity and efficacy. The majority of the existing adaptive trial designs require the toxicity/efficacy outcomes to be observed quickly, such that by the time of the next dose assignment, the outcomes of the previously treated patients have been completely observed. However, late-onset toxicities are common in phase I dose-finding studies, especially in oncology. To accommodate the settings in which toxicity may occur long after the treatment, I proposed the data-augmentation continual reassessment method for single-agent, dose-finding clinical trials. In recent decades, the rapid advancements in biomedicine have promoted the development of many biologically targeted therapies. These targeted agents, however, may work for only a subpopulation of patients characterized by particular biomarker signatures. We proposed a biomarker-based adaptive trial design to efficiently identify the subpopulation who benefit from the targeted agents of interest. Besides these examples, I am continuing working on statistical methodological research that is motivated by real-world applications. 


MDACC Faculty

Education & Training

Ph.D. - The University of Texas School of Public Health - 2012